Multi-Modality Imaging in Cardio-Rheumatology.

Abstract

Purpose of review: Our purpose was to discuss the advantages and disadvantages of various noninvasive imaging modalities in the evaluation of cardiovascular disease (CVD) in patients with autoimmune rheumatic diseases (ARDs). The detailed knowledge of imaging modalities will facilitate the diagnosis and follow up of CVD in ARDs.

Recent findings: Autoimmune Rheumatic Diseases (ARDs) are characterized by alterations in immunoregulatory system of the body. Although there is great progress in anti-rheumatic treatment, ARD patients are still at a higher risk for reduced life expectancy, compared with the general population, which is mainly due to the high incidence of CVD. Cardiovascular imaging holds the promise of early, noninvasive diagnosis and follow up of these patients. Echocardiography (echo), a cost effective, widely available imaging modality, can provide valuable early information about CVD in ARDs and motivate the use of more sophisticated investigations, if needed. Single Photon Emission tomography (SPECT) gives information about myocardial perfusion, while positron emission tomography (PET) gives information about both myocardial perfusion and inflammation with better spatial resolution and less radiation but at a higher financial cost, compared to SPECT. Computed Tomography Coronary Angiography (CTCA) is a reliable tool to rule out the presence of coronary artery disease, which has high incidence in ARD population. Lastly, Cardiovascular Magnetic Resonance (CMR) can perform function and tissue characterization evaluation in the same scan without using radiation and represents the ideal tool for serial evaluation of ARD patients. Lastly, molecular imaging holds the promise for individualized treatment in various ARDs. Cardiovascular imaging is the modern "stethoscope" of the clinicians and therefore they should be familiar with pro and contra of these modalities in order to achieve the best diagnostic and therapeutic target in ARD patients.